Cellectar Shares Gain Momentum on Promising Clinical Developments

Robust Clinical Trial Results Fuel Optimism

Cellectar Biosciences is attracting significant market attention following the release of encouraging interim data from its CLOVER-2 Phase 1b study. The trial is evaluating iopofosine I 131 in pediatric patients with high-risk glioma. Concurrently, investors are monitoring an upcoming regulatory decision from the European Medicines Agency (EMA) regarding the drug’s potential approval for treating Waldenstrom’s Macroglobulinemia.

This week, Cellectar unveiled compelling interim results from its CLOVER-2 study, which involves children and young adults with relapsed pediatric high-risk glioma. The findings demonstrate promising signals across multiple key areas, including tumor volume reduction, disease control, and extended patient survival.